Skip to content
Screener

Viking Therapeutics VKTX Retained Earnings

Retained Earnings at other companies

Eli Lilly logo
Eli LillyLLY
$31.89B+83.5%
Pfizer logo
PfizerPFE
$117.24B-2.0%
Amgen logo
AmgenAMGN
-$22.28B+13.4%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$137.96M-96.2%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
-$2.24B-17.0%
VAN
Vivani MedicalVANI
-$155.31M-21.1%

Other financials

Income statement

See full
Revenue-
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$3.88B+8.4%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0.0×
Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.

Filed
Apr 29, 2026, 9:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-193315
Line itemMarch 31,2026December 31,2025
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.00001 par value: 300,000,000 shares authorized at March 31, 2026 and December 31, 2025; 115,893,943 shares issued and outstanding at March 31, 2026 and 114,793,067 shares issued and outstanding at December 31, 202511
Additional paid-in capital1,508,6431,486,229
Accumulated deficit(1,005,871)(847,546)
Accumulated other comprehensive loss(856)378
Total stockholders’ equity501,917639,062
Total liabilities and stockholders’ equity$608,242$715,729

Item 1. Financial Statements

FAQ

What is Viking Therapeutics's retained earnings?
Viking Therapeutics (VKTX) reported retained earnings of -$1.01B in Q1 2026.
How has Viking Therapeutics's retained earnings changed year-over-year?
Viking Therapeutics's retained earnings decreased by 88.5% year-over-year, from -$533.54M to -$1.01B.
What is the long-term trend for Viking Therapeutics's retained earnings?
Over 5 years (2020 to 2025), Viking Therapeutics's retained earnings has grown at a 38.2% compound annual growth rate (CAGR), from -$168.19M to -$847.55M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Viking Therapeutics's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude